Global Leishmaniasis Treatment Market: Strategic Analysis and Forecast (2026–2036)
The Global Leishmaniasis Treatment Market was valued at USD 435.5 Million in 2025 and is projected to reach USD 780.2 Million by 2036, growing at a compound annual growth rate (CAGR) of 5.4% during the forecast period.
1. Market Overview
Leishmaniasis is a Neglected Tropical Disease (NTD) caused by protozoan parasites of the genus Leishmania. The market is primarily driven by public health initiatives, international funding, and the rising incidence of the disease in tropical and sub-tropical regions. As climate change expands the habitat of the sandfly vector, the market is shifting from traditional, toxic antimonials toward safer liposomal formulations and oral therapies.
2. Market Segmentation
By Type of Leishmaniasis:
-
Visceral Leishmaniasis (VL): Also known as Kala-azar; the most severe form, fatal if untreated.
-
Cutaneous Leishmaniasis (CL): The most common form, causing skin lesions and permanent scars.
-
Mucocutaneous Leishmaniasis (MCL): Destructive infection of the mucous membranes of the nose, mouth, and throat.
By Drug Class:
-
Antileishmanial Agents: (Liposomal Amphotericin B - the current gold standard).
-
Antimonials: (Meglumine Antimoniate, Sodium Stibogluconate).
-
Oral Drugs: (Miltefosine—gaining traction due to ease of administration).
-
Antibiotics: (Paromomycin).
-
Others: (Pentamidine, Hydroxyl Amidine Stilbene).
By Route of Administration:
-
Parenteral (Intravenous/Intramuscular): Common for severe VL cases.
-
Oral: Preferred for outpatient settings and CL treatment.
-
Topical: Ointments and cryotherapy primarily for Cutaneous Leishmaniasis.
By End-User:
-
Public Health Programs & NGOs: (Majority of procurement via WHO, UNICEF, and MSF).
-
Hospitals & Specialized Clinics.
-
Retail Pharmacies.
3. Competitive Landscape: Top Key Players
The market is characterized by a mix of multinational pharmaceutical companies and regional generic manufacturers.
-
Gilead Sciences, Inc. (Manufacturer of AmBisome®)
-
Knight Therapeutics Inc. (Owner of Impavido®/Miltefosine)
-
Albert David Ltd. (India-based leader in VL treatments)
-
Sanofi S.A.
-
Merck & Co., Inc.
-
GlaxoSmithKline plc (GSK)
-
Viatris Inc. (Mylan)
-
Gland Pharma Limited
-
Zydus Cadila
-
iCo Therapeutics Inc.
-
AEterna Zentaris AG
-
Eurofins Advinus
-
Pieris Pharmaceuticals
-
Dafra Pharma
-
Laboratório Farmacêutico do Estado de Pernambuco (LAFEPE) (Brazil)
4. Regional Analysis
-
Asia-Pacific: Historically the largest market for Visceral Leishmaniasis, particularly in the "Kala-azar" belt (India, Bangladesh, Nepal). Strong government-led elimination programs are successfully reducing incidence here.
-
Africa: The region with the highest unmet need. East Africa (Sudan, South Sudan, Ethiopia) remains a major hub for VL, while North Africa sees high rates of CL.
-
South America: Brazil accounts for nearly 90% of VL cases in the Americas. The market is driven by decentralized treatment programs.
-
Middle East: High prevalence of Cutaneous Leishmaniasis in conflict zones (Syria, Iraq, Afghanistan), leading to a surge in demand for topical and oral therapies.
-
North America & Europe: Low incidence but growing R&D. Climate change is causing sandflies to migrate northward, with emerging cases reported in Southern Europe and the Southern United States (Texas/Arizona).
5. Porter’s Five Forces Analysis
-
Threat of New Entrants (Low): High R&D costs and the "low-profit" nature of Neglected Tropical Diseases deter private startups unless backed by grants.
-
Bargaining Power of Buyers (Very High): Major buyers are the WHO, Bill & Melinda Gates Foundation, and national governments who negotiate for lowest-cost generic access.
-
Bargaining Power of Suppliers (Moderate): Limited manufacturers of specialized drugs like Liposomal Amphotericin B give suppliers some leverage.
-
Threat of Substitutes (Moderate): Traditional antimonials are being substituted by newer, less toxic oral drugs and combination therapies.
-
Competitive Rivalry (Moderate): Competition is focused on obtaining "Orphan Drug" status and securing long-term supply contracts with global health organizations.
6. SWOT Analysis
-
Strengths:
-
Established WHO-led elimination frameworks.
-
Existence of highly effective Liposomal Amphotericin B.
-
-
Weaknesses:
-
High cost of modern treatments in resource-poor settings.
-
Cold-chain requirements for parenteral drugs.
-
-
Opportunities:
-
Development of Room-temperature stable formulations.
-
AI-driven drug repurposing to find new antileishmanial properties in existing drugs.
-
-
Threats:
-
Emerging drug resistance (especially to antimonials in India).
-
Political instability in endemic regions disrupting supply chains.
-
7. Trend Analysis
-
Shift to Oral Therapy: There is a heavy R&D push to move away from painful injections toward oral Miltefosine or combination therapies to improve patient compliance.
-
Combination Protocols: Using two or more drugs (e.g., AmBisome + Miltefosine) to shorten treatment duration and prevent the development of drug resistance.
-
One Health Approach: Increasing focus on treating domestic dogs (the primary reservoir for VL in South America and Europe) to prevent human transmission.
8. Drivers & Challenges
-
Drivers:
-
Climate Change: Rising global temperatures are expanding the geographical range of the sandfly vector.
-
Government Funding: Increased focus on NTD goals (London Declaration on NTDs).
-
Urbanization: Encroachment into forested areas increasing human-vector contact.
-
-
Challenges:
-
Market Disincentives: Low ROI for pharmaceutical companies limits private investment.
-
Diagnostic Gaps: Difficulty in diagnosing VL in remote areas leads to underreporting and late treatment.
-
9. Value Chain Analysis
-
Grant-Funded R&D: Research often led by DNDi (Drugs for Neglected Diseases initiative) and academic institutes.
-
Generic Manufacturing: Production in low-cost hubs like India and Brazil.
-
Global Procurement: WHO and NGOs manage bulk purchasing.
-
Logistics: Specialized "last-mile" delivery to rural tropical clinics.
-
Patient Care: Diagnosis and treatment monitoring in public health facilities.
10. Quick Recommendations for Stakeholders
-
For Manufacturers: Focus on Generic Liposomal Formulations. As patents expire, the demand for affordable, high-quality generic injectables in Africa and Asia will be massive.
-
For NGOs/Donors: Invest in Diagnostic-Treatment Bundles. Providing rapid diagnostic kits alongside medication ensures that treatments are utilized effectively and early.
-
For Investors: Monitor companies involved in Veterinary Leishmaniasis Vaccines. Protecting the canine reservoir is becoming a primary strategy for controlling human outbreaks in Europe and Latin America.
1. Market Overview of Leishmaniasis Treatment
1.1 Leishmaniasis Treatment Market Overview
1.1.1 Leishmaniasis Treatment Product Scope
1.1.2 Market Status and Outlook
1.2 Leishmaniasis Treatment Market Size by Regions: 2015 VS 2021 VS 2026
1.3 Leishmaniasis Treatment Historic Market Size by Regions
1.4 Leishmaniasis Treatment Forecasted Market Size by Regions
1.5 Covid-19 Impact on Key Regions, Keyword Market Size YoY Growth
1.5.1 North America
1.5.2 East Asia
1.5.3 Europe
1.5.4 South Asia
1.5.5 Southeast Asia
1.5.6 Middle East
1.5.7 Africa
1.5.8 Oceania
1.5.9 South America
1.5.10 Rest of the World
1.6 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth
1.6.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
1.6.2 Covid-19 Impact: Commodity Prices Indices
1.6.3 Covid-19 Impact: Global Major Government Policy
2. Covid-19 Impact Leishmaniasis Treatment Sales Market by Type
2.1 Global Leishmaniasis Treatment Historic Market Size by Type
2.2 Global Leishmaniasis Treatment Forecasted Market Size by Type
2.3 Meglumine Antimoniate
2.4 Pentamidine
2.5 Hydroxyl Amidine Stilbene
2.6 Amphotericin B
3. Covid-19 Impact Leishmaniasis Treatment Sales Market by Application
3.1 Global Leishmaniasis Treatment Historic Market Size by Application
3.2 Global Leishmaniasis Treatment Forecasted Market Size by Application
3.3 Visceral Leishmaniasis
3.4 Cutaneous Leishmaniasis
4. Covid-19 Impact Market Competition by Manufacturers
4.1 Global Leishmaniasis Treatment Production Capacity Market Share by Manufacturers
4.2 Global Leishmaniasis Treatment Revenue Market Share by Manufacturers
4.3 Global Leishmaniasis Treatment Average Price by Manufacturers
5. Company Profiles and Key Figures in Leishmaniasis Treatment Business
5.1 Merck
5.1.1 Merck Company Profile
5.1.2 Merck Leishmaniasis Treatment Product Specification
5.1.3 Merck Leishmaniasis Treatment Production Capacity, Revenue, Price and Gross Margin
5.2 iCo Therapeutics
5.2.1 iCo Therapeutics Company Profile
5.2.2 iCo Therapeutics Leishmaniasis Treatment Product Specification
5.2.3 iCo Therapeutics Leishmaniasis Treatment Production Capacity, Revenue, Price and Gross Margin
5.3 AEterna Zentaris
5.3.1 AEterna Zentaris Company Profile
5.3.2 AEterna Zentaris Leishmaniasis Treatment Product Specification
5.3.3 AEterna Zentaris Leishmaniasis Treatment Production Capacity, Revenue, Price and Gross Margin
5.4 AEterna Zentaris AG
5.4.1 AEterna Zentaris AG Company Profile
5.4.2 AEterna Zentaris AG Leishmaniasis Treatment Product Specification
5.4.3 AEterna Zentaris AG Leishmaniasis Treatment Production Capacity, Revenue, Price and Gross Margin
5.5 Eurofins Advinus
5.5.1 Eurofins Advinus Company Profile
5.5.2 Eurofins Advinus Leishmaniasis Treatment Product Specification
5.5.3 Eurofins Advinus Leishmaniasis Treatment Production Capacity, Revenue, Price and Gross Margin
5.6 Pieris Pharmaceuticals
5.6.1 Pieris Pharmaceuticals Company Profile
5.6.2 Pieris Pharmaceuticals Leishmaniasis Treatment Product Specification
5.6.3 Pieris Pharmaceuticals Leishmaniasis Treatment Production Capacity, Revenue, Price and Gross Margin
5.7 Dafra Pharma
5.7.1 Dafra Pharma Company Profile
5.7.2 Dafra Pharma Leishmaniasis Treatment Product Specification
5.7.3 Dafra Pharma Leishmaniasis Treatment Production Capacity, Revenue, Price and Gross Margin
6. North America
6.1 North America Leishmaniasis Treatment Market Size
6.2 North America Leishmaniasis Treatment Key Players in North America
6.3 North America Leishmaniasis Treatment Market Size by Type
6.4 North America Leishmaniasis Treatment Market Size by Application
7. East Asia
7.1 East Asia Leishmaniasis Treatment Market Size
7.2 East Asia Leishmaniasis Treatment Key Players in North America
7.3 East Asia Leishmaniasis Treatment Market Size by Type
7.4 East Asia Leishmaniasis Treatment Market Size by Application
8. Europe
8.1 Europe Leishmaniasis Treatment Market Size
8.2 Europe Leishmaniasis Treatment Key Players in North America
8.3 Europe Leishmaniasis Treatment Market Size by Type
8.4 Europe Leishmaniasis Treatment Market Size by Application
9. South Asia
9.1 South Asia Leishmaniasis Treatment Market Size
9.2 South Asia Leishmaniasis Treatment Key Players in North America
9.3 South Asia Leishmaniasis Treatment Market Size by Type
9.4 South Asia Leishmaniasis Treatment Market Size by Application
10. Southeast Asia
10.1 Southeast Asia Leishmaniasis Treatment Market Size
10.2 Southeast Asia Leishmaniasis Treatment Key Players in North America
10.3 Southeast Asia Leishmaniasis Treatment Market Size by Type
10.4 Southeast Asia Leishmaniasis Treatment Market Size by Application
11. Middle East
11.1 Middle East Leishmaniasis Treatment Market Size
11.2 Middle East Leishmaniasis Treatment Key Players in North America
11.3 Middle East Leishmaniasis Treatment Market Size by Type
11.4 Middle East Leishmaniasis Treatment Market Size by Application
12. Africa
12.1 Africa Leishmaniasis Treatment Market Size
12.2 Africa Leishmaniasis Treatment Key Players in North America
12.3 Africa Leishmaniasis Treatment Market Size by Type
12.4 Africa Leishmaniasis Treatment Market Size by Application
13. Oceania
13.1 Oceania Leishmaniasis Treatment Market Size
13.2 Oceania Leishmaniasis Treatment Key Players in North America
13.3 Oceania Leishmaniasis Treatment Market Size by Type
13.4 Oceania Leishmaniasis Treatment Market Size by Application
14. South America
14.1 South America Leishmaniasis Treatment Market Size
14.2 South America Leishmaniasis Treatment Key Players in North America
14.3 South America Leishmaniasis Treatment Market Size by Type
14.4 South America Leishmaniasis Treatment Market Size by Application
15. Rest of the World
15.1 Rest of the World Leishmaniasis Treatment Market Size
15.2 Rest of the World Leishmaniasis Treatment Key Players in North America
15.3 Rest of the World Leishmaniasis Treatment Market Size by Type
15.4 Rest of the World Leishmaniasis Treatment Market Size by Application
16 Leishmaniasis Treatment Market Dynamics
16.1 Covid-19 Impact Market Top Trends
16.2 Covid-19 Impact Market Drivers
16.3 Covid-19 Impact Market Challenges
16.4 Porter
Market Segmentation
By Type of Leishmaniasis:
-
Visceral Leishmaniasis (VL): Also known as Kala-azar; the most severe form, fatal if untreated.
-
Cutaneous Leishmaniasis (CL): The most common form, causing skin lesions and permanent scars.
-
Mucocutaneous Leishmaniasis (MCL): Destructive infection of the mucous membranes of the nose, mouth, and throat.
By Drug Class:
-
Antileishmanial Agents: (Liposomal Amphotericin B - the current gold standard).
-
Antimonials: (Meglumine Antimoniate, Sodium Stibogluconate).
-
Oral Drugs: (Miltefosine—gaining traction due to ease of administration).
-
Antibiotics: (Paromomycin).
-
Others: (Pentamidine, Hydroxyl Amidine Stilbene).
By Route of Administration:
-
Parenteral (Intravenous/Intramuscular): Common for severe VL cases.
-
Oral: Preferred for outpatient settings and CL treatment.
-
Topical: Ointments and cryotherapy primarily for Cutaneous Leishmaniasis.
By End-User:
-
Public Health Programs & NGOs: (Majority of procurement via WHO, UNICEF, and MSF).
-
Hospitals & Specialized Clinics.
-
Retail Pharmacies.
3. Competitive Landscape: Top Key Players
The market is characterized by a mix of multinational pharmaceutical companies and regional generic manufacturers.
-
Gilead Sciences, Inc. (Manufacturer of AmBisome®)
-
Knight Therapeutics Inc. (Owner of Impavido®/Miltefosine)
-
Albert David Ltd. (India-based leader in VL treatments)
-
Sanofi S.A.
-
Merck & Co., Inc.
-
GlaxoSmithKline plc (GSK)
-
Viatris Inc. (Mylan)
-
Gland Pharma Limited
-
Zydus Cadila
-
iCo Therapeutics Inc.
-
AEterna Zentaris AG
-
Eurofins Advinus
-
Pieris Pharmaceuticals
-
Dafra Pharma
-
Laboratório Farmacêutico do Estado de Pernambuco (LAFEPE) (Brazil)
